Vanguard Global Advisers
STRO icon

Vanguard Global Advisers’s Sutro Biopharma STRO Stock Holding History

Vanguard Global Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$181K Sell
5,445
-1,737
-24% -$54.2K ﹤0.01% 2540
2026
Q1 		$179K Buy
+7,182
New +$130K ﹤0.01% 2486

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Vanguard Global Advisers's STRO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Sutro Biopharma (STRO) stake by 24% in Q2 2026, selling an estimated $54.2K and leaving 5,445 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #2540.

Vanguard Global Advisers first reported a position in STRO in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Vanguard Global Advisers held 5,445 shares of Sutro Biopharma worth $181K as of Q2 2026.
  • Vanguard Global Advisers sold 1,737 Sutro Biopharma shares in Q2 2026, an estimated $54.2K.
  • Sutro Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2540 holding.
  • Vanguard Global Advisers first reported a position in Sutro Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.